Oncocyte (NASDAQ:IMDX – Get Free Report) is one of 853 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Oncocyte to similar businesses based on the strength of its valuation, analyst recommendations, risk, dividends, earnings, profitability and institutional ownership.
Profitability
This table compares Oncocyte and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncocyte | -2,955.63% | N/A | -107.52% |
| Oncocyte Competitors | -8,900.43% | -205.68% | -31.56% |
Earnings and Valuation
This table compares Oncocyte and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Oncocyte | $4.05 million | -$50.22 million | -2.31 |
| Oncocyte Competitors | $682.06 million | $9.10 million | -10.45 |
Insider and Institutional Ownership
55.3% of Oncocyte shares are held by institutional investors. Comparatively, 48.0% of shares of all “Biotechnology” companies are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings for Oncocyte and its peers, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncocyte | 1 | 0 | 2 | 0 | 2.33 |
| Oncocyte Competitors | 9480 | 14972 | 45057 | 1542 | 2.54 |
Oncocyte currently has a consensus target price of $10.50, suggesting a potential upside of 205.23%. As a group, “Biotechnology” companies have a potential upside of 66.31%. Given Oncocyte’s higher possible upside, equities research analysts plainly believe Oncocyte is more favorable than its peers.
Volatility & Risk
Oncocyte has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500. Comparatively, Oncocyte’s peers have a beta of 1.11, meaning that their average stock price is 11% more volatile than the S&P 500.
Summary
Oncocyte beats its peers on 7 of the 13 factors compared.
About Oncocyte
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.
